<?xml version="1.0" encoding="UTF-8" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Cayman Journal - NovaBridge Biosciences (NBP)</title>
    <description>Latest news, press releases, and SEC filings for NovaBridge Biosciences (NBP)</description>
    <link>https://caymanjournal.com/stock/NBP</link>
    <language>en-us</language>
    
    <copyright>Copyright 2026, Cayman Journal</copyright>
    <managingEditor>editorial@caymanjournal.com (Editorial Team)</managingEditor>
    <webMaster>webmaster@caymanjournal.com (Web Master)</webMaster>
    <lastBuildDate>Mon, 27 Apr 2026 22:46:21 GMT</lastBuildDate>
    <ttl>60</ttl>
    <atom:link href="https://caymanjournal.com/stock/NBP/feed.xml" rel="self" type="application/rss+xml" />
    <image>
      <url>https://caymanjournal.com/logo.png</url>
      <title>Cayman Journal</title>
      <link>https://caymanjournal.com</link>
      <width>144</width>
      <height>144</height>
    </image>

    <item>
      <title>20-F — NovaBridge Biosciences</title>
      <description># 📄 What This Document Is
This is NovaBridge Biosciences&apos; **Form 20-F**, their annual report for the year ended December 31, 2025. It’s filed with the U.S. SEC and is required because their shares (as American Depositary Shares, or ADSs) trade on the Nasdaq. Think of it as the company’s comprehensi</description>
      <link>https://caymanjournal.com/stock/NBP/sec-filing/0001778016-26-000002</link>
      <guid isPermaLink="true">https://caymanjournal.com/stock/NBP/sec-filing/0001778016-26-000002</guid>
      <pubDate>Tue, 07 Apr 2026 00:00:00 GMT</pubDate>
      
      <category>SEC Filing</category>
      
    </item>
  </channel>
</rss>